Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Didier Laurens | M | 59 | 3 years | |
| David M. Geliebter | M | - |
Remedy Pharmaceuticals, Inc.
 Remedy Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Remedy Pharmaceuticals, Inc. develops and commercializes pharmaceutical ingridients. It focuses on small molecule drugs for acute central nervous system disorders. The company was founded by David M. Geliebter and Sven M. Jacobson in 2004 and is headquartered in New York, NY.
Critical Care Diagnostics, Inc.
 Critical Care Diagnostics, Inc. Medical SpecialtiesHealth Technology Critical Care Diagnostics, Inc. develops diagnostic tools. The firm offers Presage, a laboratory assay employing ST2 for the diagnosis and prognosis of cardiovascular disease. It also offers Aspect-PLUS ST2 test, a cardiac biomarker testing product that aids clinicians in assessing risk, making treatment decisions, evaluating therapy effectiveness, and monitoring patient care. The company was founded by Sven M. Jacobson and David M. Geliebter in 2004 and is headquartered in San Diego, CA. | 20 years |
| Sven M. Jacobson | M | - |
Remedy Pharmaceuticals, Inc.
Remedy Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Remedy Pharmaceuticals, Inc. develops and commercializes pharmaceutical ingridients. It focuses on small molecule drugs for acute central nervous system disorders. The company was founded by David M. Geliebter and Sven M. Jacobson in 2004 and is headquartered in New York, NY.
Critical Care Diagnostics, Inc.
Critical Care Diagnostics, Inc. Medical SpecialtiesHealth Technology Critical Care Diagnostics, Inc. develops diagnostic tools. The firm offers Presage, a laboratory assay employing ST2 for the diagnosis and prognosis of cardiovascular disease. It also offers Aspect-PLUS ST2 test, a cardiac biomarker testing product that aids clinicians in assessing risk, making treatment decisions, evaluating therapy effectiveness, and monitoring patient care. The company was founded by Sven M. Jacobson and David M. Geliebter in 2004 and is headquartered in San Diego, CA. | 20 years |
| Joshua Schafer | M | 53 | 4 years | |
| Hege Hellstrom | M | 59 | 4 years | |
| Hugo Brugière | M | - | 2 years | |
| Alf Gunnar Martin Nicklasson | M | 69 | 9 years | |
| Adam Sinding Steensberg | M | 50 | 14 years | |
| James Kuo | M | 58 | 2 years | |
| Michael Grissinger | M | 70 | 6 years | |
| Lawrence Steinman | M | 76 | 4 years | |
| Caroline Courme | F | - | 8 years | |
| Christian Homsy | M | 65 | 1 years | |
| Steven Romano | M | 64 | 5 years | |
| James Ede-Golightly | M | 44 | 5 years | |
| Jacques Galloy | M | 53 | 1 years | |
| Eric Floyd | M | 62 | 5 years | |
| Iain Ross | M | 71 | 5 years | |
| Abhijit Pangu | M | - | 3 years | |
| Raj Thota | M | - | 3 years | |
| Antoine Gravelle | M | - | 2 years | |
| Melissa Israel | F | - | 4 years | |
| Inge Beernaert | M | - | 1 years | |
| Laurent Cassedannemr | M | - | 3 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Daniel Cohen | M | - | 13 years | |
| Mogens Vang Rasmussen | M | - | 7 years | |
| Luc-André Granier | M | 70 | 13 years | |
| David J. Ellam | M | - | 3 years | |
| Patricia van Dijck | M | 59 | - | |
| Stephen Parker | M | 65 | 6 years | |
| Andrew Richards | M | 64 | 3 years | |
| John Hyttel | M | 78 | 15 years | |
| Per Thoresen | M | 71 |
Bionor Pharma ASA
 Bionor Pharma ASA Pharmaceuticals: OtherHealth Technology Bionor Pharma ASA engages in research and development, patenting, and commercialization of products in the pharmaceuticals and biotech industry. The company focuses on the research and development of peptide-based vaccines against viral diseases, primarily HIV. The company was founded on January 2, 1993 and is headquartered in Oslo, Norway. | - |
| Ingrid Elvira Leisner | F | 55 |
Bionor Pharma ASA
Bionor Pharma ASA Pharmaceuticals: OtherHealth Technology Bionor Pharma ASA engages in research and development, patenting, and commercialization of products in the pharmaceuticals and biotech industry. The company focuses on the research and development of peptide-based vaccines against viral diseases, primarily HIV. The company was founded on January 2, 1993 and is headquartered in Oslo, Norway. | - |
| Florian Reinaud | M | 51 | - | |
| Hanne Leth Hillman | F | 59 | 5 years | |
| Catherine Moukheibir | F | 64 | 5 years | |
| Anker Gunvald Lundemose | M | 63 |
Bionor Pharma ASA
Bionor Pharma ASA Pharmaceuticals: OtherHealth Technology Bionor Pharma ASA engages in research and development, patenting, and commercialization of products in the pharmaceuticals and biotech industry. The company focuses on the research and development of peptide-based vaccines against viral diseases, primarily HIV. The company was founded on January 2, 1993 and is headquartered in Oslo, Norway. | 2 years |
| Benedicte Fossum | F | 62 |
Bionor Pharma ASA
Bionor Pharma ASA Pharmaceuticals: OtherHealth Technology Bionor Pharma ASA engages in research and development, patenting, and commercialization of products in the pharmaceuticals and biotech industry. The company focuses on the research and development of peptide-based vaccines against viral diseases, primarily HIV. The company was founded on January 2, 1993 and is headquartered in Oslo, Norway. | 4 years |
| Caroline Roussel-Maupetit | F | - | 13 years | |
| Thomas Hofstaetter | M | 75 |
Bionor Pharma ASA
Bionor Pharma ASA Pharmaceuticals: OtherHealth Technology Bionor Pharma ASA engages in research and development, patenting, and commercialization of products in the pharmaceuticals and biotech industry. The company focuses on the research and development of peptide-based vaccines against viral diseases, primarily HIV. The company was founded on January 2, 1993 and is headquartered in Oslo, Norway. | 1 years |
| Marie-Yvonne Landel-Meunier | F | 71 | 4 years | |
| Michael Owen | M | 73 | 12 years | |
| Britt Meelby Jensen | F | 51 | 4 years | |
| Eric Pottier | M | - | 3 years | |
| Soren Keller | M | - |
Bionor Pharma ASA
Bionor Pharma ASA Pharmaceuticals: OtherHealth Technology Bionor Pharma ASA engages in research and development, patenting, and commercialization of products in the pharmaceuticals and biotech industry. The company focuses on the research and development of peptide-based vaccines against viral diseases, primarily HIV. The company was founded on January 2, 1993 and is headquartered in Oslo, Norway. | - |
| Lena Elisabeth Svanberg | M | 63 | 2 years | |
| Erik van den Eynden | M | 56 | 2 years | |
| Peter Feldschreiber | M | 81 | - | |
| Steen Kroyer | M | - |
Bionor Pharma ASA
Bionor Pharma ASA Pharmaceuticals: OtherHealth Technology Bionor Pharma ASA engages in research and development, patenting, and commercialization of products in the pharmaceuticals and biotech industry. The company focuses on the research and development of peptide-based vaccines against viral diseases, primarily HIV. The company was founded on January 2, 1993 and is headquartered in Oslo, Norway. | - |
| Liesbeth Weynants | F | 53 | 2 years | |
| An Cloet | F | 53 | 2 years | |
| Annalisa Jenkins | M | 58 | 1 years | |
| Giles Campion | M | 69 | 4 years | |
| Mats Blom | M | 59 | 9 years | |
| Piers John Morgan | M | 57 | 1 years | |
| Jørgen Lindegaard | M | 76 | - | |
| Christian Moretti | M | 78 | 2 years | |
| Kirsten Drejer | M | 68 |
Bionor Pharma ASA
Bionor Pharma ASA Pharmaceuticals: OtherHealth Technology Bionor Pharma ASA engages in research and development, patenting, and commercialization of products in the pharmaceuticals and biotech industry. The company focuses on the research and development of peptide-based vaccines against viral diseases, primarily HIV. The company was founded on January 2, 1993 and is headquartered in Oslo, Norway. | 1 years |
| Jutta af Rosenborg | F | 65 | - | |
| Robert M. Shaw | M | 70 | 2 years | |
| Michel de Rosen | M | 73 | 8 years | |
| Damian Marron | M | 62 | 2 years | |
| Jørgen Fischer Ravn | M | 55 |
Bionor Pharma ASA
Bionor Pharma ASA Pharmaceuticals: OtherHealth Technology Bionor Pharma ASA engages in research and development, patenting, and commercialization of products in the pharmaceuticals and biotech industry. The company focuses on the research and development of peptide-based vaccines against viral diseases, primarily HIV. The company was founded on January 2, 1993 and is headquartered in Oslo, Norway. | 1 years |
| Jerome Zeldis | M | 74 |
Bionor Pharma ASA
Bionor Pharma ASA Pharmaceuticals: OtherHealth Technology Bionor Pharma ASA engages in research and development, patenting, and commercialization of products in the pharmaceuticals and biotech industry. The company focuses on the research and development of peptide-based vaccines against viral diseases, primarily HIV. The company was founded on January 2, 1993 and is headquartered in Oslo, Norway. | 4 years |
| David Stout | M | 69 | 2 years | |
| Philippe Pouletty | M | 65 | 5 years | |
| Jens Krois | M | - |
Bionor Pharma ASA
Bionor Pharma ASA Pharmaceuticals: OtherHealth Technology Bionor Pharma ASA engages in research and development, patenting, and commercialization of products in the pharmaceuticals and biotech industry. The company focuses on the research and development of peptide-based vaccines against viral diseases, primarily HIV. The company was founded on January 2, 1993 and is headquartered in Oslo, Norway. | 1 years |
| Maud Bouvier | M | 46 | - | |
| Li Zhou | M | - | 2 years | |
| Jean-Christophe Renondin | M | - | 3 years | |
| Helen T. Shin | M | - |
Weill Cornell Medical College
| 4 years |
| Jorgen Wittendorff | M | - | 4 years | |
| Valérie Worrall | F | - | - | |
| Thomas Tscherning | M | - | 2 years | |
| Laura Roca-Alonso | M | - | 15 years | |
| Alexandre Berda | M | - | 2 years | |
| Amel Tounsi | M | 43 | 2 years | |
| Jens Stenvang | M | 70 | 14 years | |
| Raj Kumar Tiwari | M | 66 |
Weill Cornell Medical College
| 5 years |
| Françoise Brunner-Ferber | M | - | - | |
| Laurent Arthaud | M | 61 | 6 years | |
| Agneta Svedberg | F | 61 | - | |
| Anders Fink Vadsholt | M | 55 | - | |
| Arnaud Foussat | M | - | 13 years | |
| Julie Rachline | M | - | 5 years | |
| Gaëtan Servais | M | 56 | 2 years | |
| Peter Collum | M | - | 2 years | |
| Stéphane Boissel | M | 56 | - | |
| Arvind M. Hundal | M | 61 | - | |
| Robert M. Kotin | M | - |
Weill Cornell Medical College
| 1 years |
| Russell Greig | M | 71 |
Bionor Pharma ASA
Bionor Pharma ASA Pharmaceuticals: OtherHealth Technology Bionor Pharma ASA engages in research and development, patenting, and commercialization of products in the pharmaceuticals and biotech industry. The company focuses on the research and development of peptide-based vaccines against viral diseases, primarily HIV. The company was founded on January 2, 1993 and is headquartered in Oslo, Norway. | 1 years |
| Adrian Hepner | M | 62 | 2 years | |
| Christian Gröndahl | M | 60 | - | |
| Unni Hjelmaas | F | - |
Bionor Pharma ASA
Bionor Pharma ASA Pharmaceuticals: OtherHealth Technology Bionor Pharma ASA engages in research and development, patenting, and commercialization of products in the pharmaceuticals and biotech industry. The company focuses on the research and development of peptide-based vaccines against viral diseases, primarily HIV. The company was founded on January 2, 1993 and is headquartered in Oslo, Norway. | - |
| Catherine Mathis | M | 58 | - | |
| Jean Combalbert | M | - | 1 years | |
| Torsten Hoffmann | M | 57 | 2 years | |
| David Battleman | M | 57 |
Weill Cornell Medical College
| 3 years |
| Benedikte Bandak | F | - | 7 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| France | 36 | 36.00% |
| Denmark | 21 | 21.00% |
| Norway | 13 | 13.00% |
| United Kingdom | 11 | 11.00% |
| Belgium | 10 | 10.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- David Solomon
- Personal Network
